Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Editas Medicine, Inc. (EDIT : NSDQ)
 
 • Company Description   
Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.

Number of Employees: 264

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.02 Daily Weekly Monthly
20 Day Moving Average: 1,791,968 shares
Shares Outstanding: 68.64 (millions)
Market Capitalization: $756.42 (millions)
Beta: 2.06
52 Week High: $73.03
52 Week Low: $9.71
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.47% -17.30%
12 Week -34.79% -26.72%
Year To Date -58.49% -49.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11 Hurley Street
-
Cambridge,MA 02141
USA
ph: 617-401-9000
fax: -
ir@editasmed.com http://www.editasmedicine.com
 
 • General Corporate Information   
Officers
James C. Mullen - President and Chief Executive Officer; Chairman
Michelle Robertson - Chief Financial Officer
Meeta Chatterjee - Director
Bernadette Connaughton - Director
Andrew Hirsch - Director

Peer Information
Editas Medicine, Inc. (CORR.)
Editas Medicine, Inc. (RSPI)
Editas Medicine, Inc. (CGXP)
Editas Medicine, Inc. (BGEN)
Editas Medicine, Inc. (GTBP)
Editas Medicine, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28106W103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 68.64
Most Recent Split Date: (:1)
Beta: 2.06
Market Capitalization: $756.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.41 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: -
Price / Sales: 29.30
EPS Growth
vs. Year Ago Period: 13.95%
vs. Previous Quarter: -21.31%
Sales Growth
vs. Year Ago Period: 4.19%
vs. Previous Quarter: -45.70%
ROE
03/31/22 - -32.88
12/31/21 - -32.19
09/30/21 - -38.28
ROA
03/31/22 - -26.87
12/31/21 - -26.27
09/30/21 - -30.23
Current Ratio
03/31/22 - 13.62
12/31/21 - 10.82
09/30/21 - 11.15
Quick Ratio
03/31/22 - 13.62
12/31/21 - 10.82
09/30/21 - 11.15
Operating Margin
03/31/22 - -721.60
12/31/21 - -753.61
09/30/21 - -871.91
Net Margin
03/31/22 - -721.60
12/31/21 - -753.61
09/30/21 - -871.91
Pre-Tax Margin
03/31/22 - -721.60
12/31/21 - -753.61
09/30/21 - -871.91
Book Value
03/31/22 - 7.47
12/31/21 - 8.09
09/30/21 - 8.60
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©